Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Statistically, we know that weight loss alone doesnt fully explain the drugs effects
Long-Term Weight Loss & Maintenance with Semaglutide in Obesity (2022 Review of STEP Trials) consolidates findings across multiple STEP trials (1, 3, 4, 8), showing 14.917.4% mean weight loss over 68 weeks, improved cardiometabolic markers, and better quality-of-life outcomes
Diabetes Care, 46(8), 1516-1525
Beacon Research Solutions provides research grade peptides and supporting documentation, while also equipping independent healthcare providers, including physicians, functional medicine practices, and dietitians, with education and resources to navigate a space thats often confusing
By contrast, preclinical in vivo and in vitro studies both indicate that incretin receptor agonism can attenuate fibrogenic signalling in models of kidney disorders, and thus the positive clinical trial data on kidney function outcome measures may, in part, be mediated by inhibition of fibrosis
